Quentir Medicine Monitor
Evidence-based insights for quantum medicine. Published by Quentir Systems LLC · November 4, 2026.
Yonsei University put a new processor into its IBM quantum computer at the Songdo International Campus in Incheon and showed it to the press on 4 November 2026. The machine now runs on IBM Quantum Nighthawk r2, and the university says it will use the system to cut years from the early, computational stages of drug development.
The time targets came from Chung Jae-ho, head of Yonsei's quantum initiative, at a media briefing in Songdo. As Digital Daily reported on 4 November, he described algorithms that would shorten the target protein search from one to two years to five months, and the search for a compound and its optimization into a drug candidate from four years to two. The Seoul Economic Daily account of the same day presents both figures as goals of a pipeline that combines quantum algorithms with artificial intelligence, and quotes Chung expecting a speed gain of 40 to 50 percent over AI algorithms that industry uses as standard.
For a hospital or pharmaceutical reader, the useful part of the briefing is how carefully Chung drew the boundary of quantum drug discovery. He put the usual length of drug development at about 15 years and said that the last seven to eight, the clinical trials, are not something faster computation can shorten. Yonsei's work concentrates on the stages before any patient is involved: finding the protein that drives a disease and finding a molecule that acts on it.
What Yonsei and IBM switched on in Songdo: 120 programmable qubits, 218 couplers and a square lattice
Yonsei installed Korea's first IBM Quantum System One in 2024, built around a 127-qubit Eagle processor. Chung called the two years since then "season 1" and the upgrade "season 2." According to Seoul Economic Daily, this is the first Nighthawk processor installed in an outside institution's own facility.
IBM introduced the design in its announcement of 12 November 2025: 120 qubits linked by 218 tunable couplers, each qubit connected to up to four nearest neighbors in a square lattice, with circuits of up to 5,000 two-qubit gates at launch. On the Eagle chip each qubit reaches two or three neighbors. Better connectivity matters because qubits that are not directly linked need extra operations to exchange information, and every extra operation adds error.
Yonsei describes the chip as having 458 physical qubits. Digital Daily explains the count: 120 programmable qubits that run circuits, 218 couplers and 120 reset elements. The 120 computing qubits are physical qubits without error correction, so they are a different unit from the logical qubits that a fault-tolerant machine would use. IBM plans to expand beyond 500 programmable qubits, connect several processors past 1,000 qubits, and build a large error-corrected computer by 2029.
Quantum pillar: computing. Technology readiness: TRL 3 of 9. This is Quentir's assessment for quantum methods in drug-target and compound discovery: the hardware runs, and the Yonsei algorithms exist as research work, but the 4 November briefing, as reported, cited no published study showing them finding a target or a drug candidate faster than classical methods in a real development program.
What the 25-fold figure measures: circuits per second against IBM's earlier Heron processor
The number in most headlines is a 25-fold improvement. Jerry Chow, chief technology officer for quantum-centric supercomputing at IBM Research, said the system can run up to 100,000 circuits per second by using fast reset, which he described as 25 times the speed of the earlier Heron generation without a loss in gate quality. Digital Daily makes the limit explicit: the figure compares how quickly circuits can be repeated, and the effect on the time a research project takes depends on the task. Chow cited one task, a neutron-scattering simulation at Oak Ridge National Laboratory, which ran 12 times faster than an earlier experiment on Heron.
That distinction carries straight into medicine. A drug-discovery calculation spends time on classical preprocessing, on many repeated quantum runs, and on classical work that turns noisy samples into an answer. Faster circuit throughput shortens only one part of that chain. The five-month target for target search is therefore a claim about Yonsei's whole pipeline, and the briefing did not point to a paper, a benchmark or a specific drug-development program that shows it. Season 2 has a stated aim of confirming quantum advantage, meaning a quantum computer doing better than classical computers on a specific problem. IBM itself expects the first verified cases of quantum advantage to be confirmed by the wider community by the end of 2026.
Yonsei's announced targets exclude clinical development. The US Food and Drug Administration describes five steps of drug development: discovery and development, preclinical research, clinical research, FDA review, and post-market safety monitoring. Yonsei's targets fall inside the first step. A two-year saving there is valuable to a developer, and it still leaves phase I to phase III trials and regulatory review between a promising molecule and a patient.
How Yonsei links Songdo to RIKEN's Fugaku supercomputer and opens the system to outside users
Chung said current quantum computers on their own face limits on hard problems, so Yonsei has built a hybrid computing platform. The Songdo system is connected over a network to Fugaku, the supercomputer of Japan's RIKEN. At the opening, the two machines exchanged data live: the quantum computer produced samples and Fugaku used them for the follow-on calculation. Yonsei and RIKEN have also agreed to joint research on treatments for intractable diseases.
Access reaches beyond the campus. Outside users apply through a committee that reviews eligibility and research content, then use the system over the cloud. Chung said bio and pharmaceutical companies, universities, research institutes and national agencies already use it. He reported about 2,000 people trained each year, around 100 research papers on quantum algorithms in the past year and a half across physics, chemistry, materials, finance, biology and drug development, and about 50 master's and doctoral students in the graduate program in quantum information science. Yonsei is also in talks with the University of Cambridge on a Cambridge quantum institute at Songdo and a branch of Yonsei's quantum medicine institute in Cambridge.
Nighthawk processors are already reaching medical research elsewhere. In September Quentir looked at how Rensselaer Polytechnic Institute and Kipu Quantum ran autism biomarker selection on IBM's 120-qubit Nighthawk processors, a preprint that came with data and methods a reader could check. That is the kind of evidence the Songdo claims still need.
How Quentir Reads It
Yonsei now holds an on-site Nighthawk processor, a live link to Fugaku and an open access route for companies, which gives Songdo the hardware, the classical partner and the access route needed to test quantum methods on biological problems. The drug-discovery figures from the 4 November briefing are targets stated by the program's own leader, and they are honest about their scope, since Chung excluded the clinical years himself. A pharmaceutical partner or hospital research office weighing access should ask for the first published comparison: one disease target, the Yonsei hybrid pipeline against a strong classical baseline, with the time saved measured from start to a validated hit. Until such a study appears, the five-month and two-year figures remain targets set by the program itself.
Sources
Primary source: the Digital Daily report by Lee An-na of 4 November 2026 on the Yonsei University media briefing in Songdo. Also drawn on: the Seoul Economic Daily report of the same day, IBM's Nighthawk announcement of 12 November 2025, the US Food and Drug Administration overview of the drug development process, and earlier Quentir coverage.